Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire.
The purpose of this study was to describe the results of Nd:YAG laser application in hereditary hemorrhagic telangiectasia (HHT) patients and to measure the Health-Related Quality of Life (HR-QoL) in patients with HHT before and after Nd:YAG laser application in a prospective, clinical trial at a university hospital. Twenty-seven consecutive patients with HHT and mild to moderate degrees of epistaxis were followed-up for 2 years after Nd:YAG laser treatments. Recurrence of epistaxis after Nd:YAG laser application and measurement of HR-QoL using the International Quality of Life Assessment questionnaire, version 1.1 (IQOLA 1.1), was found. Eight patients (30%) received only one Nd:YAG laser treatment, 15 (56%) had a recurrence and received a second treatment and 4 (14%) had two recurrences and received three Nd:YAG laser treatments. HR-QoL was improved 2 years after the first Nd:YAG laser application in both its Physical Health Dimension (47.5+/-2.9 vs. 38.1+/-2.3 before treatment, P <0.05) and Mental Health Dimension (45.1+/-2.7 vs. 39.6+/-2.4 before treatment, P <0.05). Although no curative treatment for HHT exists, Nd:YAG laser treatment seems to constitute a simple and efficient method of epistaxis control, resulting in a significant improvement in quality of life.
Karapantzos
Ilias
I
Department of Otorhinolaryngology, Demokritous University of Thrace, Ioakim Kaviri 6, 68100, Alexandroupoli, Greece.
Tsimpiris
Nikolaos
N
Goulis
Dimitrios G
DG
Van Hoecke
Helen
H
Van Cauwenberge
Paul
P
Danielides
Vasilis
V
D004844:Epistaxis / Q000209:etiology / Q000523:psychology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053685:Laser Therapy / Q000379:methods* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011788:Quality of Life; D012008:Recurrence; D012086:Reoperation; D011795:Surveys and Questionnaires; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000175:diagnosis / Q000523:psychology / Q000601:surgery*; D016896:Treatment Outcome
Am J Rhinol. 1997 Jan-Feb;11(1):55-62
9065348
South Med J. 1996 Jan;89(1):78-80
8545698
Laryngoscope. 1990 Sep;100(9):953-7
2395404
Int J Oral Maxillofac Surg. 1989 Apr;18(2):117-20
2501405
Harefuah. 2003 Dec;142(12):852-6, 876
14702755
HNO. 1998 Mar;46(3):228-32
9583027
J Laryngol Otol. 1997 Jan;111(1):34-7
9292128
Radiol Med. 1995 Jun;89(6):861-4
7644743
Arch Intern Med. 1996 Apr 8;156(7):714-9
8615703
Laryngoscope. 2002 May;112(5):767-73
12150604
Curr Opin Hematol. 1998 Sep;5(5):332-8
9776212
Am J Med Genet. 2000 Mar 6;91(1):66-7
10751092
Am J Otolaryngol. 1995 Mar-Apr;16(2):138-40
7793510
Ann Otol Rhinol Laryngol. 2002 Mar;111(3 Pt 1):222-8
11913682
Laryngorhinootologie. 1997 Aug;76(8):495-501
9376034
J Otolaryngol. 1995 Oct;24(5):299-302
8537990
Ann Plast Surg. 1995 Aug;35(2):208-13
7486747
Am J Rhinol. 1999 Jul-Aug;13(4):319-22
10485021